Xanomeline and trospium chloride

Brand names: Cobenfy · Active ingredient: Xanomeline, Trospium Chloride

In short: COBENFY is indicated for the treatment of schizophrenia in adults.

Forms & strengthsCOBENFY is available as: •50 mg/20 mg (xanomeline/trospium chloride): Buff capsules imprinted with Karuna 50/20 mg •100 mg/20 mg (xanomeline/trospium chloride): Brown capsules imprinted with Karuna 100/20 mg •125 mg/30 mg (xanomeline/trospium chloride): …
LabelE.R. Squibb & Sons, L.L.C.
Label updatedAug 21, 2026

What is Xanomeline and trospium chloride used for?

COBENFY is indicated for the treatment of schizophrenia in adults.

Xanomeline and trospium chloride dosage

•Assess liver enzymes and bilirubin prior to initiating COBENFY and as clinically indicated during treatment .

•Assess heart rate at baseline and as clinically indicated during treatment .

The recommended dosage of COBENFY is as follows:

•The recommended starting dosage is one 50 mg/20 mg capsule (contains 50 mg of xanomeline and 20 mg of trospium chloride) orally twice daily for at least two days.

•Increase the dosage to one 100 mg/20 mg capsule (contains 100 mg of xanomeline and 20 mg of trospium chloride) orally twice daily for at least five days.

•The dosage may be increased to one 125 mg/30 mg capsule (contains 125 mg of xanomeline and 30 mg of trospium chloride) orally twice daily based on patient tolerability and response .

•Maximum recommended dosage is 125 mg/30 mg orally twice daily.

Administer COBENFY orally at least one hour before a meal or at least two hours after a meal . Do not open the capsules.

The recommended starting dosage of COBENFY in geriatric patients is one 50 mg/20 mg capsule orally twice daily. Consider a slower titration for geriatric patients. The maximum recommended dosage in geriatric patients is one 100 mg/20 mg capsule twice daily .

How to take Xanomeline and trospium chloride — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Risk of Urinary Retention

Inform patients that COBENFY may cause urinary retention and that the risk of urinary retention is greater in some patients, including geriatric patients and those with bladder outlet obstruction (e.g., due to BPH) and patients with other causes of reduced bladder emptying (e.g., diabetic cystopathy). Urinary retention may occur at any time during treatment with COBENFY and is more likely when taking higher doses.

Advise patients to monitor for symptoms of urinary retention, such as urinary hesitancy, weak urinary stream, incomplete bladder emptying and pain with urination, and to promptly report these symptoms to their healthcare provider. Inform patients that urinary retention may increase the risk of urinary tract infection. Advise patients to seek immediate medical attention if they are unable to urinate . …

Warnings & precautions

Do not take this medicine if: COBENFY is contraindicated in patients with:

•urinary retention .

•moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment .

•gastric retention .

•history of hypersensitivity to COBENFY or trospium chloride. Angioedema has been reported with COBENFY and trospium chloride .

•untreated narrow-angle glaucoma .

COBENFY can cause urinary retention . Geriatric patients and patients with clinically significant bladder outlet obstruction and incomplete bladder emptying (e.g., patients with benign prostatic hyperplasia (BPH), diabetic cystopathy) may be at increased risk of urinary retention .

COBENFY is contraindicated in patients with pre-existing urinary retention and is not recommended in patients with moderate or severe renal impairment .

In patients taking COBENFY, monitor for symptoms of urinary retention, including urinary hesitancy, weak stream, incomplete bladder emptying, and dysuria. Instruct patients to be aware of the risk and promptly report symptoms of urinary retention to their healthcare provider. Urinary retention is a known risk factor for urinary tract infections. In patients with symptoms of urinary retention, consider reducing the dose of COBENFY, discontinuing COBENFY, or referring patients for urologic evaluation as clinically indicated.

Patients with hepatic impairment have higher systemic exposures of xanomeline, a component of COBENFY, compared to patients with normal hepatic function, which may result in increased incidence of COBENFY-related adverse reactions .

COBENFY is contraindicated in patients with moderate or severe hepatic impairment . COBENFY is not recommended in patients with mild hepatic impairment .

Assess liver enzymes prior to initiating COBENFY and as clinically indicated during treatment. …

Xanomeline and trospium chloride side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

•Risk of Urinary Retention

•Risk of Use in Patients with Hepatic Impairment

•Risk of Use in Patients with Biliary Disease

•Decreased Gastrointestinal Motility

•Risk of Angioedema

•Risk of Use in Patients with Narrow-angle Glaucoma

•Increases in Heart Rate

•Anticholinergic Adverse Reactions in Patients with Renal Impairment

•Central Nervous System Effects

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

COBENFY was evaluated for safety in a total of 1,594 subjects exposed to one or more doses, including 1,135 adult patients with schizophrenia and 389 healthy subjects. A total of 347 COBENFY-treated patients had at least 6 months of exposure and 150 patients had at least 1 year of exposure (defined as ≥ 50 weeks) from open-label studies.

The adverse reaction findings are based on two pooled 5-week, placebo-controlled, flexible-dose studies in 504 adult patients with schizophrenia in which COBENFY or placebo was started at an initial dose of 50 mg/20 mg twice daily for the first 2 days followed by 100 mg/20 mg twice daily for the remainder of Week 1 (Days 3 to 7). On Day 8, dosing was titrated to 125 mg/30 mg twice daily unless the patient could not tolerate it. …

Drug interactions

Table 2 displays clinically significant drug interactions with COBENFY.

Strong Inhibitors of CYP2D6

Clinical Implication: | CYP2D6 contributes significantly to the metabolism of xanomeline, a component of COBENFY. Concomitant use of COBENFY with strong CYP2D6 inhibitors may increase plasma concentrations of xanomeline, which may increase the frequency and/or severity of adverse reactions from COBENFY .

Prevention or Management: | Monitor patients for increased frequency and/or severity of adverse reactions related to COBENFY in patients taking COBENFY with strong inhibitors of CYP2D6.

Drugs Eliminated by Active Tubular Secretion

Clinical Implication: | Concomitant use of COBENFY with drugs that are eliminated by active tubular secretion may increase plasma concentrations of trospium a component of COBENFY, and/or the concomitantly used drug due to competition for this elimination pathway, which may increase the frequency and/or severity of adverse reactions from COBENFY or the drug eliminated by active tubular secretion .

Prevention or Management: | Monitor patients for increased frequency and/or severity of adverse reactions related to COBENFY and adverse reactions related to drugs eliminated by active tubular secretion in patients concomitantly receiving such drugs. …

About this medicine

COBENFY is a combination of xanomeline, a muscarinic agonist, and trospium chloride, a muscarinic antagonist.

The chemical name of xanomeline tartrate is pyridine, 3-[4-(hexyloxy)-1,2,5-thiadiazol-3-yl]-1,2,5,6-tetrahydro-1-methyl-, (2R,3R)-2,3-dihydroxybutanedioate (1:1). Its molecular formula is C14H23N3OS.C4H6O6 and its molecular weight is 431.51 g/mol. Xanomeline tartrate is a white to slightly tan crystalline solid. Xanomeline tartrate is highly soluble in protic solvents, such as methanol and water, and in polar organic solvents such as DMF and dimethyl sulfoxide (DMSO). It is poorly soluble in lipophilic organic solvents, such as hexane or octanol.

The chemical structure of xanomeline tartrate is:

Trospium chloride is a quaternary ammonium compound with the chemical name of spiro[8-azoniabicyclo[3.2.1]octane-8,1′-pyrrolidinium], 3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-, chloride (1:1), (1α,3β,5α). The molecular formula of trospium chloride is C25H30NO3.Cl and its molecular weight is 427.96 g/mol. Trospium chloride is a fine, colorless to slightly yellow, crystalline solid. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 8f0e73bf-6025-44f6-ab64-0983322de0df. Read the full official label on DailyMed.

Related medicines

Sertraline Escitalopram Bupropion Fluoxetine Trazodone Duloxetine Prednisone Buspirone